Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
October 04, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
September 21, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
September 06, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
August 15, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were...
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
June 30, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001...
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
June 07, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on...
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
June 01, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 16:01 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Changes to Board of Directors
May 17, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...